Natalizumab to fingolimod: Questions answered, unanswered, and unasked

Affiliations

• ¹ From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR. olaf.stuve@utsouthwestern.edu.
• ² From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR.